TOP HEADLINES

Editor's Corner

Emergent BioSolutions nabs government funds to test new-and-improved anthrax vaccine

In a $31 million development agreement with Emergent BioSolutions announced Monday, the Department of Health and Human Services said it will fund Phase III development for NuThrax, Emergent's new anthrax vaccine that's already been funded through Phase I and II by the NIH and the Department of Defense.

GlaxoSmithKline takes TB vaccine to Phase IIb

BCG (Bacille Calmette-Guérin) is the only WHO-approved tuberculosis vaccine and is given to infants, but has proven ineffective in adults. Enter GlaxoSmithKline, which, along with Aeras and Kenya Medical Research Institute, will roll their candidate in Phase IIb trials in Kenya.

Sanofi continues pediatric vaccine push with FDA Quadracel nod

Sanofi Pasteur counts pediatric vaccines among its 5 key areas, and it's bolstering its offerings in the field with Wednesday's FDA approval of the Quadracel vaccine.

Chinese Ebola vaccine based on current strain looks safe in PhI

Results from the Phase I trial of yet another experimental Ebola vaccine are in, but unlike other vaccines in the field, this one is based on the virus strain that caused the 2014 epidemic, and not an older one. The vaccine, developed by Beijing Institute of Biotechnology and Tianjin CanSino Biotechnology, is called a recombinant adenovirus type-5 vaccine.

Germany's cost watchdog decides Valeant's Provenge has added benefit after all

In January, Germany's cost watchdog decided that Dendreon's--now Valeant's--Provenge had no added benefit for men with metastatic prostate cancer. But now, it's changing its tune.

MORE NEWS

From Our Sister Sites

FierceBiotech

In this week's EuroBiotech Report, Malin pulled in a blockbuster €330 million IPO, putting it among the biggest ever European biotech listings. Malin is targeting pre-IPO biotechs, a group that will find it easier to access public markets if a European equivalent of the JOBS Act, the U.S. legislative rethink that opened the current biotech IPO window, is passed. And more.

FierceMedicalDevices

Hearing devices have not been among Medtronic's competencies--until now. The medical device giant has bought magnetic hearing implant startup Sophono for an undisclosed amount. Sophono's implant is the smallest and most effective at higher frequencies, according to the startup and Medtronic.